CompletedPHASE1, PHASE2NCT02421367

Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

Studying Dengue fever

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
U.S. Army Medical Research and Development Command
Principal Investigator
Leyi Lin, M.D.
USAMRMC/WRAIR
Intervention
TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.(biological)
Enrollment
140 enrolled
Eligibility
20-49 years · All sexes
Timeline
20152018

Study locations (2)

Collaborators

Walter Reed Army Institute of Research (WRAIR) · GlaxoSmithKline

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02421367 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever

← Back to all trials